SpyGlass Pharma Announces Pricing of Initial Public Offering
I'm PortAI, I can summarize articles.
SpyGlass Pharma, a late-stage biopharmaceutical company, has priced its initial public offering (IPO) at $16.00 per share, aiming to raise approximately $150 million. The offering includes 9,375,000 shares, with an option for underwriters to purchase an additional 1,406,250 shares. Trading on the Nasdaq under the ticker "SGP" is set to begin on February 6, 2026, with the offering expected to close on February 9, 2026. Jefferies, Leerink Partners, Citigroup, and Stifel are the joint book-running managers for the IPO.
Source: fidelity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments